{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:58Z","timestamp":1790916838197,"version":"4.1.0"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The ductus arteriosus is a vital fetal vessel connecting the pulmonary artery\nto the aorta, facilitating blood flow away from the non-functional fetal lungs. Drug exposure during\npregnancy may affect DA physiology, leading to conditions like premature DA closure, DA stenosis,\nor Patent Ductus Arteriosus (PDA). To identify drugs with maternal exposure that may be linked to\nalterations in the fetal and neonatal Ductus Arteriosus (DA). This study examines associations between\nvarious drugs and alterations in DA using data from the USFDA Adverse Event Reporting\nSystem (AERS) through disproportionality analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from March 2004 to June 2024 were extracted from the AERS database, focusing on\nMedDRA Preferred Terms (PTs) for PDA, DA premature closure, and DA stenosis, combined with\n\u201cfetal exposure during pregnancy.\u201d Following deduplication, 1,878 unique cases (PDA: 1,444; DA\nstenosis: 213; DA closure: 221) were analyzed. Disproportionality signals were detected using frequentist\n[Reporting Odds Ratio and Proportional Reporting Ratio (PRR)] and Bayesian (Bayesian\nConfidence Propagation Neural Network and Multi-Item Gamma Poisson Shrinker) methods to assess\nassociations. Signals were considered when there were at least three cases, a PRR value of \u2265 2,\nand a Chi-square (\u03c72) value of \u2265 4 according to Evan\u2019s criteria. Amongst the Bayesian methods, signals\nwere considered when the lower limit of the IC\u2019s 95% CI (IC025) &gt;0 and the lower limit of the\n95% CI of the Empirical Bayes Geometric Mean (EBGM05) exceeded 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Diclofenac had the highest number of reports for DA stenosis (number of reports: 118; PRR:\n163; \u03c72: 8401.7; IC025: 4.7; and EBGM05: 55.9) and premature closure stenosis (number of reports:\n68; PRR: 58.3; \u03c72: 2612.8; IC025: 4; and EBGM05: 30.6). Drugs linked with DA stenosis included\nanalgesics (e.g., acetaminophen), antiemetics, and anti-inflammatory agents (e.g., ibuprofen). Premature\nDA closure was associated with analgesics, anti-inflammatory drugs, and psychoanaleptics. For\nPDA, signals were detected for a broad spectrum of drugs, including analgesics, antibacterials, anesthetics,\nantiepileptics, and antihypertensives. PDA cases showed a significantly higher rate of mortality\ncompared to other DA conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>These findings highlighted significant associations between maternal drug exposure and\nDA alterations, reinforcing known risks (such as NSAID-induced DA closure) and suggesting potential\nsignals for SSRIs and antiepileptics. These results align with established pharmacological mechanisms\nand regulatory warnings, but must be interpreted cautiously given the limitations of spontaneous\nreporting data. The study underscores the need for targeted fetal monitoring, provider education,\nand prospective research to validate signals and refine drug safety guidelines in pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This disproportionality analysis identified significant associations between maternal\ndrug exposure and alterations in the fetal and neonatal DA, including premature closure, stenosis, and\nPDA. The findings highlighted the need for further pharmacovigilance studies to validate these signals,\nparticularly for drugs with strong disproportionality signals but limited mechanistic evidence.\nFuture research should focus on prospective cohort studies and mechanistic investigations to clarify\ncausality and assess clinical implications. Additionally, risk-benefit evaluations of drug use during\npregnancy, especially for analgesics, anti-inflammatory agents, and psychoanaleptics, are warranted\nto guide safer therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115701611369928250804093531","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:00:16Z","timestamp":1755252016000},"page":"128-140","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ductus Arteriosus Variability Linked to Maternal Drug Exposure: Assessment of the USFDA Adverse Event Reporting System using Disproportionality Analysis"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":true,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[{"name":"Department of Pharmacology &amp; Therapeutics, College of Medicine &amp; Health Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Gillam-Krakauer M.","year":"2024","unstructured":"Gillam-Krakauer M.; Mahajan K.; Patent Ductus Arteriosus. In: StatPearls  2024","journal-title":"In: StatPearls"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1203\/00006450-199805000-00012","volume":"43","author":"Clyman R.I.","year":"1998","unstructured":"Clyman R.I.; Waleh N.; Black S.M.; Riemer R.K.; Mauray F.; Chen Y.Q.; Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: The role of gestation, oxygen tension, and vasa vasorum. Pediatr Res  1998,43(5),633-44","journal-title":"Pediatr Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/sj.bjp.0705092","volume":"138","author":"Leonhardt A.","year":"2003","unstructured":"Leonhardt A.; Glaser A.; Wegmann M.; Schranz D.; Seyberth H.; N\u00fcsing R.; Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol  2003,138(4),655-9","journal-title":"Br J Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2352-4642(19)30402-X","volume":"4","author":"Zimmerman M.S.","year":"2020","unstructured":"Zimmerman M.S.; Smith A.G.C.; Sable C.A.; Global, regional, and national burden of congenital heart disease, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health  2020,4(3),185-200","journal-title":"Lancet Child Adolesc Health"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5863\/1551-6776-12.3.138","volume":"12","author":"Dice J.E.","year":"2007","unstructured":"Dice J.E.; Bhatia J.; Patent ductus arteriosus: An overview. J Pediatr Pharmacol Ther  2007,12(3),138-46","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00431-022-04549-x","volume":"181","author":"Deng Y.","year":"2022","unstructured":"Deng Y.; Zhang H.; Zhao Z.; Du J.; Bai R.; McNamara P.J.; Impact of patent ductus arteriosus shunt size and duration on risk of death or severe respiratory morbidity in preterm infants born in China. Eur J Pediatr  2022,181(8),3131-40","journal-title":"Eur J Pediatr"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"025784","DOI":"10.1161\/JAHA.122.025784","volume":"11","author":"Backes C.H.","year":"2022","unstructured":"Backes C.H.; Hill K.D.; Shelton E.L.; Patent ductus arteriosus: A contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc  2022,11(17),025784","journal-title":"J Am Heart Assoc"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e20153730","DOI":"10.1542\/peds.2015-3730","volume":"137","author":"Benitz W.E.","year":"2016","unstructured":"Benitz W.E.; Patent ductus arteriosus in preterm infants. Pediatrics  2016,137(1),e20153730","journal-title":"Pediatrics"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/eurheartj\/ehp128","volume":"30","author":"Gewillig M.","year":"2009","unstructured":"Gewillig M.; Brown S.C.; De Catte L.; Premature foetal closure of the arterial duct: Clinical presentations and outcome. Eur Heart J  2009,30(12),1530-6","journal-title":"Eur Heart J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.semperi.2010.02.007","volume":"34","author":"Reese J.","year":"2010","unstructured":"Reese J.; Veldman A.; Shah L.; Vucovich M.; Cotton R.B.; Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period. Semin Perinatol  2010,34(3),222-30","journal-title":"Semin Perinatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bcpt.13308","volume":"127","author":"Mirabito Colafella K.M.","year":"2020","unstructured":"Mirabito Colafella K.M.; Neuman R.I.; Visser W.; Danser A.H.J.; Versmissen J.; Aspirin for the prevention and treatment of pre\u2010eclampsia: A matter of COX\u20101 and\/or COX\u20102 inhibition? Basic Clin Pharmacol Toxicol  2020,127(2),132-41","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"H572","DOI":"10.1152\/ajpheart.00822.2015","volume":"311","author":"Hooper C.W.","year":"2016","unstructured":"Hooper C.W.; Delaney C.; Streeter T.; Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero. Am J Physiol Heart Circ Physiol  2016,311(3),H572-81","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=13","year":"2021","unstructured":"FDA\u2019s adverse event reporting system (FAERS).  Available from:  https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers2021"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"Montastruc J.L.","year":"2011","unstructured":"Montastruc J.L.; Sommet A.; Bagheri H.; Lapeyre-Mestre M.; Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol  2011,72(6),905-8","journal-title":"Br J Clin Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"Brown E.G.","year":"1999","unstructured":"Brown E.G.; Wood L.; Wood S.; The medical dictionary for regulatory activities (MedDRA). Drug Saf  1999,20(2),109-117","journal-title":"Drug Saf"},{"key":"ref=16","year":"2023","unstructured":"FDA adverse event reporting system (FAERS) public dashboard.  Available from:  https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard2023"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"Faillie J.L.","year":"2019","unstructured":"Faillie J.L.; Case\u2013non-case studies: Principle, methods, bias and interpretation. Therapie  2019,74(2),225-32","journal-title":"Therapie"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/1097-0258(20001215)19:23<3199::AID-SIM621>3.0.CO;2-Q","volume":"19","author":"Evans S.J.W.","year":"2000","unstructured":"Evans S.J.W.; Pharmacovigilance: A science or fielding emergencies? Stat Med  2000,19(23),3199-209","journal-title":"Stat Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/pharmacy9010060","volume":"9","author":"Hollingworth S.","year":"2021","unstructured":"Hollingworth S.; Kairuz T.; Measuring medicine use: Applying atc\/ddd methodology to real-world data. Pharmacy  2021,9(1),60","journal-title":"Pharmacy"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"Fusaroli M.","year":"2024","unstructured":"Fusaroli M.; Salvo F.; Begaud B.; The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (readus-pv): Explanation and elaboration. Drug Saf  2024,47(6),585-99","journal-title":"Drug Saf"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/1471-0528.12682","volume":"121","author":"Ban L.","year":"2014","unstructured":"Ban L.; Gibson J.E.; West J.; Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: A population\u2010based cohort study. BJOG  2014,121(12),1471-81","journal-title":"BJOG"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMoa052744","volume":"354","author":"Chambers C.D.","year":"2006","unstructured":"Chambers C.D.; Hernandez-Diaz S.; Van Marter L.J.; Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med  2006,354(6),579-87","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/children4080063","volume":"4","author":"Mathew B.","year":"2017","unstructured":"Mathew B.; Lakshminrusimha S.; Persistent pulmonary hypertension in the newborn. Children  2017,4(8),63","journal-title":"Children"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000350979","volume":"34","author":"Karadeniz C.","year":"2013","unstructured":"Karadeniz C.; Ozdemir R.; Kurtulmus S.; Doksoz O.; Yozgat Y.; Mese T.; Diclofenac-induced intrauterine ductal closure. Fetal Diagn Ther  2013,34(2),133-4","journal-title":"Fetal Diagn Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0002-9378(97)70184-4","volume":"177","author":"Vermillion S.T.","year":"1997","unstructured":"Vermillion S.T.; Scardo J.A.; Lashus A.G.; Wiles H.B.; The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol  1997,177(2),256-61","journal-title":"Am J Obstet Gynecol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"0295897","DOI":"10.1371\/journal.pone.0295897","volume":"19","author":"Louchet M.","year":"2024","unstructured":"Louchet M.; Collier M.; Beeker N.; Trends in harmful drug exposure during pregnancy in France between 2013 and 2019: A nationwide cohort study. PLoS One  2024,19(1),0295897","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/1471-0528.15872","volume":"126","author":"Dathe K.","year":"2019","unstructured":"Dathe K.; Frank J.; Padberg S.; Negligible risk of prenatal ductus arteriosus closure or fetal renal impairment after third\u2010trimester paracetamol use: Evaluation of the German Embryotox cohort. BJOG  2019,126(13),1560-7","journal-title":"BJOG"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0090-6980(83)90200-9","volume":"26","author":"Momma K.","year":"1983","unstructured":"Momma K.; Takeuchi H.; Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins  1983,26(4),631-43","journal-title":"Prostaglandins"},{"key":"ref=29","first-page":"48","volume":"61","author":"Begum S.","year":"2013","unstructured":"Begum S.; Thomas S.V.; Women with epilepsy in reproductive age group: Special issues and management strategies. J Assoc Physicians India  2013,61(8),48-51","journal-title":"J Assoc Physicians India"},{"key":"ref=30","year":"2025","unstructured":"Diclofenac USFDA label.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019201s038lbl.pdf (Accessed on 24th Mach 2025).2025"},{"key":"ref=31","year":"2023","unstructured":"Indomethacin USFDA label.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018829s022lbl.pdf (Accessed on 24th March 2025).2023"},{"key":"ref=32","year":"2021","unstructured":"Sertraline USFDA label.  Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839s74s86s87_20990s35s44s45lbl.pdf (Accessed on 24th March 2025).2021"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611369928250804093531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244558\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611369928250804093531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:03:56Z","timestamp":1790913836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244558\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611369928250804093531","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}